J M Gallo

Author PubWeight™ 72.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994 1.80
2 Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci Lett 1988 1.77
3 Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain 1991 1.74
4 A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength. Pharm Res 1990 1.64
5 Brain diseases. Ubiquitous variations in nerves. Nature 1989 1.53
6 Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 1996 1.49
7 Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001 1.38
8 In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem 1996 1.31
9 Interactions of valproic acid with phenytoin. Neurology 1980 1.24
10 3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. AIDS Res Hum Retroviruses 1990 1.24
11 Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol Ther 2007 1.22
12 Developmental changes in tau phosphorylation: fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of Alzheimer's disease. J Neurochem 1993 1.18
13 Distribution of small magnetic particles in brain tumor-bearing rats. J Neurooncol 1999 1.08
14 Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996 1.07
15 Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp 2001 1.06
16 Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J Biol Chem 1996 1.01
17 Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 1999 0.97
18 Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole. Pharm Res 1992 0.95
19 Tau isoform expression and phosphorylation state during differentiation of cultured neuronal cells. FEBS Lett 1995 0.94
20 Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. Biochem J 1991 0.94
21 Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J Drug Target 1998 0.94
22 The phosphorylation state of the microtubule-associated protein tau as affected by glutamate, colchicine and beta-amyloid in primary rat cortical neuronal cultures. Biochem J 1995 0.93
23 Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 1996 0.92
24 In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol 1996 0.91
25 Pharmacokinetics of 2',3'-dideoxyinosine in monkeys. Antimicrob Agents Chemother 1991 0.91
26 High-performance liquid chromatographic determination of the calcium channel blocker nimodipine in monkey plasma. J Chromatogr 1992 0.90
27 Truncated forms of the androgen receptor are associated with polyglutamine expansion in X-linked spinal and bulbar muscular atrophy. Hum Mol Genet 1998 0.88
28 Pharmacokinetic evaluation of drug interactions with zidovudine. I: Probenecid and zidovudine in monkeys. J Pharm Sci 1991 0.88
29 Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. J Med Chem 1990 0.88
30 Comparative pharmacokinetics and interspecies scaling of 3'-azido-3'-deoxythymidine (AZT) in several mammalian species. J Pharmacobiodyn 1990 0.88
31 Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. Clin Exp Metastasis 1998 0.87
32 A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res., 56: 4686-4693, 1996. Cancer Res 1997 0.86
33 Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res 1996 0.86
34 Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis. J Chromatogr B Biomed Sci Appl 1997 0.86
35 Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol 2001 0.86
36 Effect of parameter variability on physiologically-based pharmacokinetic model predicted drug concentrations. J Pharm Sci 1995 0.85
37 A subpopulation of trypanosome microtubules recognized by a monoclonal antibody to tubulin. EMBO J 1983 0.85
38 Application of microdialysis to characterize drug disposition in tumors. Adv Drug Deliv Rev 2000 0.84
39 NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data. J Pharm Sci 1996 0.84
40 Effect of increased glycogen synthase kinase-3 activity upon the maturation of the amyloid precursor protein in transfected cells. Neuroreport 1997 0.84
41 Effect of dosing vehicles on the pharmacokinetics of orally administered carbon tetrachloride in rats. Toxicol Appl Pharmacol 1990 0.84
42 Comparative pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU) in mice. Drug Metab Dispos 1990 0.83
43 Homologies between paraflagellar rod proteins from trypanosomes and euglenoids revealed by a monoclonal antibody. Eur J Cell Biol 1985 0.83
44 Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 2000 0.83
45 Physiological pharmacokinetic modeling of inhaled trichloroethylene in rats. Toxicol Appl Pharmacol 1991 0.83
46 Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys. Pharm Res 1992 0.83
47 Stimulation of MAP kinase by v-raf transformation of fibroblasts fails to induce hyperphosphorylation of transfected tau. FEBS Lett 1995 0.83
48 Adenoviral modification of mouse brain derived endothelial cells, bEnd3, to induce apoptosis by vascular endothelial growth factor. Oncogene 2006 0.82
49 Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol 2001 0.82
50 Enhanced brain delivery of an anti-HIV nucleoside 2'-F-ara-ddI by xanthine oxidase mediated biotransformation. J Med Chem 1994 0.81
51 Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 1996 0.81
52 Ibuprofen kinetics in plasma and synovial fluid of arthritic patients. J Clin Pharmacol 1986 0.80
53 Androgen-induced up-regulation of tubulin isoforms in neuroblastoma cells. J Neurochem 2001 0.80
54 Proacrosin as a marker of meiotic and post-meiotic germ cell differentiation: quantitative assessment of human spermatogenesis with a monoclonal antibody. J Reprod Fertil 1994 0.79
55 Characterization of presystemic elimination of trichloroethylene and its nonlinear kinetics in rats. Toxicol Appl Pharmacol 1996 0.79
56 Androgen-controlled specific gene expression in neuroblastoma cells. J Neurol Sci 1995 0.79
57 Targeting anticancer drugs to the brain. I: Enhanced brain delivery of oxantrazole following administration in magnetic cationic microspheres. J Drug Target 1993 0.79
58 Human acrosome biogenesis: immunodetection of proacrosin in primary spermatocytes and of its partitioning pattern during meiosis. Development 1991 0.79
59 Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate. J Med Chem 1997 0.78
60 Zalcitabine. Clinical pharmacokinetics and efficacy. Clin Pharmacokinet 1995 0.78
61 Identification of novel in vitro PKA phosphorylation sites on the low and middle molecular mass neurofilament subunits by mass spectrometry. Biochemistry 1998 0.78
62 Immunochemical characterization of a human sperm fibrous sheath protein, its developmental expression pattern, and morphogenetic relationships with actin. J Histochem Cytochem 1997 0.78
63 Incorporation of NF-L into keratin filaments in transfected epithelial cells. Neuroreport 1997 0.77
64 Mutually exclusive expression of beta(III)-tubulin and vimentin in adrenal cortex carcinoma SW13 cells. FEBS Lett 2000 0.77
65 Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys. Drug Metab Dispos 1992 0.77
66 Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose. Clin Cancer Res 2000 0.77
67 Synthesis, characterization, and in vitro stability of chitosan-methotrexate conjugates. Pharm Res 1990 0.77
68 Use of a physiologically based model to predict systemic uptake and respiratory elimination of perchloroethylene. Toxicol Appl Pharmacol 1994 0.77
69 Unexplained in-vitro fertilization failure: implication of acrosomes with a small reacting region, as revealed by a monoclonal antibody. Hum Reprod 1992 0.76
70 Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res 1996 0.76
71 Modulation of PHF-like tau phosphorylation in cultured neurones and transfected cells. Neurobiol Aging 1995 0.76
72 Aggregation of neurofilaments in NF-L transfected neuronal cells: regeneration of the filamentous network by a protein kinase C inhibitor. J Neurochem 1996 0.76
73 Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J Neurooncol 1995 0.76
74 Cytoplasmic events in human meiotic arrest as revealed by immunolabelling of spermatocyte proacrosin. Differentiation 1992 0.76
75 The ins and outs of antiviral drug transport in the brain. J Neurovirol 1997 0.75
76 Preparation and in vitro evaluation of magnetic microsphere-methotrexate conjugate drug delivery systems. Bioconjug Chem 1995 0.75
77 Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats. Cancer Chemother Pharmacol 1994 0.75
78 Ubiquitin, PGP 9.5 and dense body formation in trimethyltin intoxication: differential neuronal responses to chemically induced cell damage. Neuropathol Appl Neurobiol 1992 0.75
79 Effect of phenytoin on protein binding of valproic acid. Can J Neurol Sci 1979 0.75
80 High-performance liquid chromatographic analysis of the anticancer drug oxantrazole in rat whole blood and tissues. J Chromatogr 1992 0.75
81 Comparison of cortical bone and serum concentrations of clindamycin achievable by direct local infusion and intravenous administration. J Orthop Res 1991 0.75
82 Delivery of cytotoxic drugs from carrier cells to tumour cells by apoptosis. Apoptosis 1998 0.75
83 Use of capillary electrophoresis methods to characterize the pharmacokinetics of antisense drugs. Electrophoresis 1998 0.75
84 Pharmacokinetics of anti-HIV nucleosides in microswine. J Pharm Pharmacol 1991 0.75
85 Immunochemical and immunocytochemical studies of the crustacean vitellogenesis-inhibiting hormone (VIH). Gen Comp Endocrinol 1987 0.75
86 Pharmacokinetics and tissue distribution of a DNA-methyltransferase antisense (MT-AS) oligonucleotide and its catabolites in tumor-bearing nude mice. J Pharmacol Exp Ther 1997 0.75
87 High-performance liquid chromatographic method for the determination of AG-331, a novel anti-cancer agent, in human serum and urine using solid-phase extraction and photodiode-array detection. J Chromatogr B Biomed Appl 1995 0.75
88 The uptake and elimination of 1,1,1-trichloroethane during and following inhalation exposures in rats. Toxicol Appl Pharmacol 1989 0.75
89 Effect of dietary fat content on the bioavailability of a sustained release quinidine gluconate tablet. Biopharm Drug Dispos 1990 0.75
90 Differential distribution of tubulin epitopes in human spermatozoa. Eur J Cell Biol 1986 0.75
91 Changes in inert gas rebreathing parameters after ozone exposure in dogs. Am Rev Respir Dis 1983 0.75
92 Rapid and simultaneous determination of zidovudine and its glucuronide metabolite in plasma and urine. Application to the pharmacokinetic interaction of zidovudine and probenecid in the monkey. J Pharm Biomed Anal 1991 0.75